Synthetic Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients
Article Information
vol. 25 no. 2 376-380
PubMed
Published By
Print ISSN
Online ISSN
History
- Published in print February 1, 2002.
Copyright & Usage
© 2002
Author Information
- Wei-Shiung Yang, MD, PHD12,
- Chi-Yuan Jeng, MD, PHD3,
- Ta-Jen Wu, MD, PHD4,
- Sachiyo Tanaka, MD, PHD5,
- Tohru Funahashi, MD, PHD5,
- Yuji Matsuzawa, MD, PHD5,
- Jao-Ping Wang, BS1,
- Chi-Ling Chen, PHD6,
- Tong-Yuan Tai, MD, PHD1 and
- Lee-Ming Chuang, MD, PHD12
- 1Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
- 2Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
- 3Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan
- 4Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan, Taiwan
- 5Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan
- 6Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
Statistics from Altmetric.com
Article usage
In this Issue
February 2002, 25(2)
Synthetic Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients
